PLRX
Pliant Therapeutics Inc
0.99$
-3.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Pliant Therapeutics Inc (PLRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -13 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 | -28 | -11 | -14 | -15 | 37 | -13 | 7.8 | -16 | -16 | -14 | -19 | -23 | -20 | -20 | -24 | -18 | -31 | -30 | -25 | -36 | -25 | -30 | -45 | -32 | -48 | -49 | -41 | -21 | -18 | -19 | -13 | -71 | |
| 0.1 | 0.7 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.2 | 1.3 | |
| 0.0 | – | 0.3 | 0.5 | 0.5 | 0.5 | 0.4 | 0.8 | 1.2 | 1.5 | 2.6 | 2.3 | 2.8 | 2.8 | 3.5 | 3.4 | 4.8 | 11 | 12 | 13 | 10 | 9.2 | 9.7 | 11 | 8.9 | 8.4 | 8.9 | 6.4 | 6.4 | 4.5 | 4.3 | 4.2 | 19 | |
| 0.0 | – | 0.3 | 0.5 | 0.5 | – | 0.4 | 0.8 | 1.2 | 1.8 | 2.6 | 2.5 | 2.8 | 2.8 | 3.5 | 3.4 | 4.5 | 11 | 12 | 13 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.9 | – | 2.6 | 1.0 | -2.4 | -6.2 | -25 | 24 | -0.8 | 0.4 | 5.6 | 0.4 | 0.5 | -0.5 | 3.1 | 0.7 | 7.0 | -6.5 | -3.1 | 6.2 | -2.4 | 0.6 | 4.7 | -1.7 | 14 | -8.2 | -4.2 | -6.9 | -2.7 | -2.0 | -4.9 | 4.4 | -5.2 | |
| 0.9 | 2.3 | 0.3 | 0.5 | 0.0 | 0.2 | 0.3 | 0.3 | 0.3 | 0.6 | 0.2 | 0.6 | 0.5 | 0.6 | 0.6 | 0.3 | 0.7 | 0.2 | 0.2 | 0.6 | 0.1 | 0.1 | 1.5 | 1.3 | 0.9 | 0.2 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.9 | -2.3 | -27 | 4.9 | 14 | -9.2 | -11 | -106 | -105 | 12 | 12 | 3.6 | 32 | 26 | 1.5 | 6.5 | -178 | 20 | -174 | -23 | 38 | 32 | 60 | 11 | 31 | 39 | 69 | 35 | 28 | 1.8 | -4.1 | 15 | 41 | |
| 19 | 87 | – | – | – | 48 | 52 | – | – | – | 1.4 | 0.4 | 0.7 | 0.1 | 0.1 | 0.4 | 217 | -1.9 | 270 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 10 | 10 | 10 | 9.9 | -0.2 | -0.2 | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -32 | – | – | – | |
| 19 | 87 | -0.1 | -0.8 | -0.4 | 47 | 52 | 164 | -2.4 | 0.2 | 1.4 | 0.2 | 0.4 | 0.5 | -0.2 | 10 | 216 | 0.3 | 273 | 0.2 | 0.7 | 0.2 | 22 | 0.7 | 0.5 | 0.1 | 0.5 | 0.0 | 0.1 | -32 | 0.1 | 0.0 | -32 | |
| 11 | 57 | -38 | -9.6 | -1.5 | 74 | 28 | 65 | -123 | -4.3 | -0.1 | -16 | 10 | 6.4 | -19 | -7.5 | 20 | -11 | 69 | -48 | 2.7 | 5.6 | 51 | -34 | -0.8 | -8.4 | 21 | -5.1 | 6.9 | -48 | -23 | 2.7 | -62 | |
| -8.5 | – | -11 | -14 | -15 | 37 | -13 | 7.5 | -16 | -17 | -14 | -20 | -23 | -20 | -21 | -25 | -19 | -31 | -30 | -25 | -36 | -25 | -32 | -47 | -33 | -48 | -49 | -41 | -21 | -18 | -19 | -13 | -71 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.